A phase I clinical trial of ixotatug vedotin for the treatment of advanced cancers (NCT05103683) revealed favorable safety profiles and preliminary efficacy across CLDN6-positive ovarian, endometrial and testicular cancer patients (Konecny et al., 2024). This evidence concerns the gene CLDN6 and cancer.